Scantek Announces Additional Launch of BreastCare in South America.DENVILLE, N.J.--(BUSINESS WIRE)--Oct. 14, 1998--Scantek Medical Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : SKML SKML Singapore Kadayanallur Muslim League ) announced today that on Sept. 20, 1998 the BreastCare(TM) product was introduced at the XI Congresso Brazileiro de Mastologia in Foz do Iguacu, Brazil. This marks the official launch of BreastCare(TM) in Brazil. Scantek, along with Sandell Corp. S.A., Scantek's South American licensee, and Farmacotecnica Instituto de Manipulacoes, the sub licensee of Sandell, exhibited at the congress. More than twelve hundred physicians were in attendance, including Dr. Jose Pinotti and Dr. Alfredo Barros, newly elected president of the Brazilian Mastology Association. Both physicians are affiliated with Hospital Perola Byington in San Paulo, Brazil where clinical studies with approximately three thousand women have commenced to establish the protocol for the BreastCare(TM) device in a clinical hospital environment. This launch for the Brazilian target market was a very important step in physician education for using the BreastCare(TM) product adjunctively with clinical examination, including palpation palpation /pal·pa·tion/ (pal-pa´shun) the act of feeling with the hand; the application of the fingers with light pressure to the surface of the body for the purpose of determining the condition of the parts beneath in physical diagnosis. , mammography mammography, diagnostic procedure that uses low-dose X rays to detect abnormalities in the breasts. The early diagnosis of breast cancer made possible by the routine use of mammography for screening women increases a woman's treatment alternatives and improves her , and other screening modalities Modalities The factors and circumstances that cause a patient's symptoms to improve or worsen, including weather, time of day, effects of food, and similar factors. used to detect breast disease. Pinotti stated in the San Paulo Geral International newspaper, "BreastCare(TM) will give more chances to detect smaller tumors while the cancer is still curable cur·a·ble adj. Capable of being cured or healed. . In Brazil, 90% of breast cancer detected is in an advanced stage while in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. only 10% is. In San Paulo, two million women are at risk for developing breast cancer." Zsigmond L. Sagi, the company's president, chief executive officer and the inventor of BreastCare(TM), said, "The receptiveness and eagerness to use BreastCare(TM) was overwhelming at the congress. Over 400 physicians visited our exhibition booth on opening day inquiring about BreastCare(TM) and its availability in Brazil." "I am very pleased with the progress the company has made in Brazil. After meeting with Dr. Pinotti and Dr. Barros at the Hospital Perola Byington ,where over 3,000 indigent indigent 1) n. a person so poor and needy that he/she cannot provide the necessities of life (food, clothing, decent shelter) for himself/herself. 2) n. one without sufficient income to afford a lawyer for defense in a criminal case. women are screened daily, I truly believe that BreastCare(TM) can make a difference in early detection when used adjunctly with clinical palpation and mammography." About the company: Scantek Medical Inc. is a high-tech medical company organized to develop, manufacture, sell and license products and devices to assist in the diagnosis and early detection of disease. At the present time, the Company is focused on manufacturing, selling and licensing the BreastCare(TM) device in certain international markets. The BreastCare(TM) device is to be used by physicians as an adjunct to clinical breast examination, mammography and other established procedures for the detection of breast disease. Certain statements in this press release with respect to future expectations and plans may be regarded as "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such statements including, but not limited to, statements with respect to future earnings, and all other forward-looking statements involve risks and uncertainties and are subject to change at any time. The Company's actual results could differ materially from such statements. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion